

Patent Application
Attorney Docket No. PC23223A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 16th day of

By

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Robert L. Dow

Examiner: Unknown

APPLICATION NO.: 10/679,878

FILING DATE: October 6, 2003

:Group Art Unit: Unknown

TITLE: Cannabinoid Receptor Ligands and Uses Thereof

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.


A prompt and favorable response is earnestly solicited.

Respectfully submitted,


Date: January 16, 2004

Arlene K. Musser
Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895


Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 715-0871




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878		
		APPLICANT ROBERT L. DOW				
		FILING DATE 10/06/03		GROUP Not Available		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 20030199536 A1	10/23/03	Thomas, et al.			
	US 20030139386 A1	07/24/03	Cote, et al.			
	US 20030114495 A1	06/19/03	Finke, et al.			
	US 20030055033 A1	03/20/03	Achard, et al.			
	US 20030003145 A1	01/02/03	Abramovici, et al.			
	US 20020119972 A1	08/29/02	Leftheris, et al.			
	US 20020188007 A1	12/12/02	Barth, et al.			
	US 20020035102 A1	03/21/02	Achard, et al.			
	US 20020019383 A1	02/14/02	Achard, et al.			
	US 20010053788 A1	12/20/01	Lange, et al.			
	US 20010027193 A1	10/04/01	Achard, et al.			
	US 20020128302 A1	09/12/02	Maruani, et al.			
	US 20030078289 A1	04/24/03	Aspnes, et al.			
	US 20030064990 A1	04/03/03	Denton, et al.			
	US 20030055062 A1	03/20/03	Stamford, et al.			
	US 20030040535 A1	02/27/03	Aspnes, et al.			
	US 20030022891 A1	01/30/03	Palani, et al.			
	US 20030013720 A1	01/16/03	Hobbs, et al.			
	US 20030004162 A1	01/02/03	Treadway, et al.			
	US 2002091114 A1	07/11/02	Plot-Grosjean, et al.			
	US 20020198223 A1	12/26/02	Allerton, et al.			
	US 20020198152 A1	12/26/02	Hadcock, et al.			



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878		
		APPLICANT ROBERT L. DOW				
		FILING DATE 10/06/03		GROUP Not Available		
	US 20020193388 A1	12/19/02	Maw, et al.			
	US 20020177599 A1	11/28/02	Allerton, et al.			
	US 20020173502 A1	11/21/02	Allerton, et al.			
	US 20020169192 A1	11/14/02	Hayward, et al.			
	US 20020169101 A1	11/14/02	Gonzalez, et al.			
	US 20020165282 A1	11/07/02	Hayward, et al.			
	US 20020165237 A1	11/07/02	Fryburg, et al.			
	US 20020165223 A1	11/07/02	Greenlee, et al.			
	US 20020147336 A1	10/10/02	Dow, et al.			
	US 20020143015 A1	10/03/02	Fryburg, et al.			
	US 20020132806 A1	09/19/02	Ruggeri, et al.			
	US 20020128247 A1	09/12/02	Dow, et al.			
	US 20020107235 A1	08/08/02	Liu, et al.			
	US 20020094992 A1	07/18/02	MacLean, et al.			
	US 20020091129 A1	07/11/02	Boolell, et al.			
	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
	US 20020065277 A1	05/30/02	Hadcock, et al.			
	US 20020052392 A1	05/02/02	Day, et al.			
	US 20020052370 A1	05/02/02	Barber, et al.			
	US 20020049226 A1	04/25/02	Chiang, et al.			
	US 20020028799 A1	03/07/02	Naylor, et al.			
	US 20020035153 A1	03/21/02	Cornelius, et al.			
	US 20020019421 A1	02/14/02	Biberman, et al.			
	US 20020006946 A1	01/17/02	Aspnes, et al.			




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878		
		APPLICANT ROBERT L. DOW				
		FILING DATE 10/06/03		GROUP Not Available		
	US 20010051657 A1	12/13/01	Chiang, et al.			
	US 20010051645 A1	12/13/01	Demuth, et al.			
	US 20010046956 A1	11/29/01	Hadcock, et al.			
	US 6,566,356 B2	05/20/03	Achard, et al.			
	US 6,518,264 B2	02/11/03	Achard, et al.			
	US 6,509,367 B1	01/21/03	Martin, et al.			
	US 6,479,479 B2	11/12/02	Achard, et al.			
	US 6,476,060 B2	11/05/02	Lange, et al.			
	US 6,432,984 B1	08/13/02	Barth, et al.			
	US 6,355,631 B1	03/12/02	Bouchard, et al.			
	US 6,100,259	08/08/00	Xiang, et al.			
	US 6,028,084	02/22/00	Barth, et al.			
	US 5,925,768	07/20/99	Barth, et al.			
	US 5,747,524	05/05/98	Cullinan, et al.			
	US 5,744,493	04/28/98	Boigegrain, et al.			
	US 5,744,491	04/28/98	Boigegrain, et al.			
	US 5,624,941	04/29/97	Barth, et al.			
	US 5,596,106	01/21/97	Cullinan, et al.			
	US 5,462,960	10/31/95	Barth, et al.			
	US 4,925,846	05/15/90	Deacon, et al.			
	US 5,134,142	07/28/92	Matsuo, et al.			
	US 4,944,790	07/31/90	Moser, et al.			
	US 6,344,474 B1	02/05/02	Maruani, et al.			
	US 6,555,578 B2	04/29/03	Cornelius, et al.			




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878	
		APPLICANT ROBERT L. DOW			
		FILING DATE 10/06/03		GROUP Not Available	

	US 6,545,018 B2	04/08/03	Chiang, et al.			
	US 6,514,966 B2	02/04/03	Elliott, et al.			
	US 6,451,783 B1	09/17/02	Hadcock, et al.			
	US 6,441,015 B2	08/27/02	Aspnes, et al.			
	US 6,380,223 B1	04/30/02	Dow, et al.			
	US 6,369,075 B1	04/09/02	Ruggeri, et al.			
	US 6,355,635 B1	03/12/02	Elliott, et al.			
	US 6,344,481 B1	02/05/02	Cornelius, et al.			
	US 6,326,398 B1	12/04/01	Chiang, et al.			
	US 6,194,454 B1	02/27/01	Dow, et al.			


FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
WO 03/087037 A1	10/23/03	PCT					
WO 03/086288 A2	10/23/03	PCT					
WO 03/084943 A2	10/16/03	PCT					
WO 03/082833 A1	10/09/03	PCT				X	
WO 03/082191 A2	10/09/03	PCT					
WO 03/082190 A2	10/09/03	PCT					
WO 03/078413 A1	09/25/03	PCT					
WO 03/077847 A2	09/25/03	PCT					
WO 03/051851 A1	06/26/03	PCT					
WO 03/051850 A1	06/26/03	PCT					




INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878			
		APPLICANT ROBERT L. DOW					
		FILING DATE 10/06/03		GROUP Not Available			
	WO 03/040107 A1	05/15/03	PCT				
	WO 03/027114 A1	04/03/03	PCT				
	WO 03/027076 A2	04/03/03	PCT				
	WO 03/027069 A1	04/03/03	PCT				
	WO 03/026648 A1	04/03/03	PCT				
	WO 03/026647 A1	04/03/03	PCT				
	WO 03/020217 A2	03/13/03	PCT				
	WO 03/007887 A2	01/30/03	PCT				
	WO 03/006007 A1	01/23/03	PCT				
	WO 02/076949 A1	10/03/02	PCT				
	WO 01/032663 A2	05/10/01	PCT				
	WO 01/032629 A1	05/10/01	PCT				
	WO 01/029007 A1	04/26/01	PCT				
	CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
	WO 00/15609 A1	05/23/00	PCT				x
	WO 96/02248 A1	02/01/96	PCT				
	WO 03/027114 A1	04/03/03	PCT				
	EP 293,220 B1	8/31/94	EP				
	WO 03/082256 A2	10/09/03	PCT				
	WO 03/018060 A1	03/06/03	PCT				
	WO 01/85092 A2	11/15/01	PCT				
	WO 01/24798 A1	04/12/01	PCT				
	WO 01/58450 A2	08/16/01	PCT				x
	WO 03/075660 A1	09/18/03	PCT				



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A		SERIAL NO. 10/679878			
		APPLICANT ROBERT L. DOW					
		FILING DATE 10/06/03		GROUP Not Available			
	WO 03/020314 A1	03/13/03	PCT				
	WO 03/020314 A1	03/13/03	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , 138 , 544-553 (2003).						
	Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , 23 (6), 2453-2458 (2003).						
	Crocì, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , 140 , 115-122 (2003).						
	DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Lett</u> , 349 , 49-52 (2003).						
	Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , 100 (3), 1393-1398 (2003).						
	Ruiu, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , 306 , 363-370 (2003).						
	Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , 54 , 161-202 (2002).						
	Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , 22 (21), 9612-9617 (2002).						
	Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , 296 (3), 1013-1022 (2001).						
	Lellemann, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , 25 (9), 1317-1323 (2001).						
	Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <u>Gut</u> , 48 , 859-867 (2001).						
	Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , 9 (7), 1573-1571 (2000).						
	Hungund, B.L and B.S. Basavarajappa, "Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol & Alcoholism</u> , 35 (2) 126-133, (2000).						
	Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , 67 , 265-270 (2000).						



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC23223A	SERIAL NO. 10/679878
			APPLICANT ROBERT L. DOW	
			FILING DATE 10/06/03	GROUP Not Available
		Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem.</u> , 42 , 769-776 (1999).		
		Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem.</u> , 6 , 635-664 (1999).		
		Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res.</u> , 793 , 212-218 (1998).		
		Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap.</u> , 285 , 285-292 (1998).		
		Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci.</u> , 63 , PL113-PL117 (1998);		
		Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmose," <u>Behav. Pharmacol.</u> , 9 , 179-181 (1998).		
		Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , 135 , 324-332 (1998).		
		Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol.</u> , 132 , 104-106 (1997).		
		Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol.</u> , 328 , 207-215 (1997).		
		Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Lett.</u> , 223 , 125-128 (1997).		
		Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Slices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther.</u> , 277 , 1431-1436 (1996).		
		Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther.</u> , 277 , 586-594 (1996).		
		Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , 124 , 315-322 (1996).		
		Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , 126 , 125-131 (1996).		
		Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , 7 , 65-71 (1996).		
		Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci.</u> , 56 , 1941-1947 (1995).		
		Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci.</u> , 56 , 1949-1955 (1995).		
		Rinaldi-Carmona, M., et al., "SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , 350 , 240-244 (1994).		



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC23223A	SERIAL NO. 10/679878
		APPLICANT ROBERT L. DOW	
		FILING DATE 10/06/03	GROUP Not Available
		Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A", <u>Med. Chem. Rev.</u> 5 , 54-62 (1994).	
		Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem.</u> 32 , 2116-2128 (1989).	
		Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem.</u> 26 , 1389 (1989).	
		Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , 38(2)m 151-178 (1986).	
		Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophylic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , 29 (1) 129-136 (1983).	
		Birkofer, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> 112 , 2829-2836 (1979).	
		Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfachbindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> 112 , 3623-3636 (1979).	
		Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> 112 , 1712-1718 (1979).	
EXAMINER _____ DATE CONSIDERED _____			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			